Is PYXS or FBRX more profitable?

Forte Biosciences' return on equity of -106.17% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Pyxis Oncology N/A -135.60% -85.00% Forte Biosciences N/A -106.17% -85.50%

Does the media favor PYXS or FBRX?

In the previous week, Forte Biosciences had 1 more articles in the media than Pyxis Oncology. MarketBeat recorded 3 mentions for Forte Biosciences and 2 mentions for Pyxis Oncology. Forte Biosciences' average media sentiment score of 0.61 beat Pyxis Oncology's score of 0.00 indicating that Forte Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Forte Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PYXS or DNA?

In the previous week, Ginkgo Bioworks had 2 more articles in the media than Pyxis Oncology. MarketBeat recorded 4 mentions for Ginkgo Bioworks and 2 mentions for Pyxis Oncology. Ginkgo Bioworks' average media sentiment score of 0.00 beat Pyxis Oncology's score of 0.00 indicating that Ginkgo Bioworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ginkgo Bioworks 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PYXS or IMMX more profitable?

Immix Biopharma's return on equity of -73.24% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Pyxis Oncology N/A -135.60% -85.00% Immix Biopharma N/A -73.24% -59.20%

Does the media favor PYXS or IMMX?

In the previous week, Immix Biopharma had 1 more articles in the media than Pyxis Oncology. MarketBeat recorded 3 mentions for Immix Biopharma and 2 mentions for Pyxis Oncology. Immix Biopharma's average media sentiment score of 0.93 beat Pyxis Oncology's score of 0.00 indicating that Immix Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immix Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, PYXS or ALT?

Pyxis Oncology has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pyxis Oncology $13.86M 10.28 -$79.62M -$1.31 N/A Altimmune $40K 13,661.52 -$88.09M -$0.93 N/A

Is PYXS or ALT more profitable?

Pyxis Oncology has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Pyxis Oncology N/A -135.60% -85.00% Altimmune -214,860.98% -42.57% -35.57%

Is PYXS or CTNM more profitable?

Contineum Therapeutics' return on equity of -27.09% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Pyxis Oncology N/A -135.60% -85.00% Contineum Therapeutics N/A -27.09% -25.64%

Pyxis Oncology (PYXS) Competitors

$2.25 -0.11 (-4.66%)

Closing price 04:00 PM Eastern

Extended Trading

$2.31 +0.06 (+2.44%)

As of 07:34 PM Eastern

Compare

PYXS vs. FBRX, DNA, IMMX, ALT, and CTNM

Should you buy Pyxis Oncology stock or one of its competitors? MarketBeat compares Pyxis Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pyxis Oncology include Forte Biosciences (FBRX), Ginkgo Bioworks (DNA), Immix Biopharma (IMMX), Altimmune (ALT), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical products" industry.

How does Pyxis Oncology compare to Forte Biosciences?

Pyxis Oncology (NASDAQ:PYXS) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

In the previous week, Forte Biosciences had 1 more articles in the media than Pyxis Oncology. MarketBeat recorded 3 mentions for Forte Biosciences and 2 mentions for Pyxis Oncology. Forte Biosciences' average media sentiment score of 0.61 beat Pyxis Oncology's score of 0.00 indicating that Forte Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pyxis Oncology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Forte Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Forte Biosciences has lower revenue, but higher earnings than Pyxis Oncology. Forte Biosciences is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	10.28	-$79.62M	-$1.31	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A

39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are held by institutional investors. 5.7% of Pyxis Oncology shares are held by company insiders. Comparatively, 4.4% of Forte Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Pyxis Oncology has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.85, indicating that its share price is 185% more volatile than the broader market.

Pyxis Oncology presently has a consensus target price of $6.86, suggesting a potential upside of 204.76%. Forte Biosciences has a consensus target price of $67.00, suggesting a potential upside of 41.08%. Given Pyxis Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Pyxis Oncology is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Forte Biosciences' return on equity of -106.17% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-135.60%	-85.00%
Forte Biosciences	N/A	-106.17%	-85.50%

Summary

Pyxis Oncology beats Forte Biosciences on 8 of the 14 factors compared between the two stocks.

How does Pyxis Oncology compare to Ginkgo Bioworks?

Pyxis Oncology (NASDAQ:PYXS) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Pyxis Oncology has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Ginkgo Bioworks' return on equity of -56.08% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-135.60%	-85.00%
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%

In the previous week, Ginkgo Bioworks had 2 more articles in the media than Pyxis Oncology. MarketBeat recorded 4 mentions for Ginkgo Bioworks and 2 mentions for Pyxis Oncology. Ginkgo Bioworks' average media sentiment score of 0.00 beat Pyxis Oncology's score of 0.00 indicating that Ginkgo Bioworks is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pyxis Oncology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ginkgo Bioworks	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pyxis Oncology presently has a consensus target price of $6.86, suggesting a potential upside of 204.76%. Ginkgo Bioworks has a consensus target price of $8.50, suggesting a potential upside of 12.36%. Given Pyxis Oncology's stronger consensus rating and higher probable upside, research analysts clearly believe Pyxis Oncology is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Pyxis Oncology has higher earnings, but lower revenue than Ginkgo Bioworks. Pyxis Oncology is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	10.28	-$79.62M	-$1.31	N/A
Ginkgo Bioworks	$170.15M	2.90	-$312.76M	-$5.36	N/A

Pyxis Oncology has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 5.7% of Pyxis Oncology shares are held by insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Ginkgo Bioworks beats Pyxis Oncology on 9 of the 16 factors compared between the two stocks.

How does Pyxis Oncology compare to Immix Biopharma?

Pyxis Oncology (NASDAQ:PYXS) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Pyxis Oncology has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

Immix Biopharma has lower revenue, but higher earnings than Pyxis Oncology. Immix Biopharma is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	10.28	-$79.62M	-$1.31	N/A
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A

Immix Biopharma's return on equity of -73.24% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-135.60%	-85.00%
Immix Biopharma	N/A	-73.24%	-59.20%

Pyxis Oncology currently has a consensus price target of $6.86, suggesting a potential upside of 204.76%. Immix Biopharma has a consensus price target of $20.67, suggesting a potential upside of 134.85%. Given Pyxis Oncology's higher possible upside, research analysts clearly believe Pyxis Oncology is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Immix Biopharma had 1 more articles in the media than Pyxis Oncology. MarketBeat recorded 3 mentions for Immix Biopharma and 2 mentions for Pyxis Oncology. Immix Biopharma's average media sentiment score of 0.93 beat Pyxis Oncology's score of 0.00 indicating that Immix Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pyxis Oncology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immix Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

39.1% of Pyxis Oncology shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 5.7% of Pyxis Oncology shares are owned by company insiders. Comparatively, 30.3% of Immix Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Immix Biopharma beats Pyxis Oncology on 7 of the 12 factors compared between the two stocks.

How does Pyxis Oncology compare to Altimmune?

Pyxis Oncology (NASDAQ:PYXS) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

Pyxis Oncology has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market. Comparatively, Altimmune has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market.

Pyxis Oncology has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	10.28	-$79.62M	-$1.31	N/A
Altimmune	$40K	13,661.52	-$88.09M	-$0.93	N/A

Pyxis Oncology presently has a consensus price target of $6.86, suggesting a potential upside of 204.76%. Altimmune has a consensus price target of $15.71, suggesting a potential upside of 459.23%. Given Altimmune's stronger consensus rating and higher probable upside, analysts clearly believe Altimmune is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Altimmune	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 5.7% of Pyxis Oncology shares are held by insiders. Comparatively, 1.6% of Altimmune shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Pyxis Oncology has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-135.60%	-85.00%
Altimmune	-214,860.98%	-42.57%	-35.57%

In the previous week, Pyxis Oncology had 2 more articles in the media than Altimmune. MarketBeat recorded 2 mentions for Pyxis Oncology and 0 mentions for Altimmune. Pyxis Oncology's average media sentiment score of 0.00 equaled Altimmune'saverage media sentiment score.

Company	Overall Sentiment
Pyxis Oncology	Neutral
Altimmune	Neutral

Summary

Altimmune beats Pyxis Oncology on 8 of the 15 factors compared between the two stocks.

How does Pyxis Oncology compare to Contineum Therapeutics?

Pyxis Oncology (NASDAQ:PYXS) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

39.1% of Pyxis Oncology shares are owned by institutional investors. 5.7% of Pyxis Oncology shares are owned by insiders. Comparatively, 7.9% of Contineum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Pyxis Oncology had 2 more articles in the media than Contineum Therapeutics. MarketBeat recorded 2 mentions for Pyxis Oncology and 0 mentions for Contineum Therapeutics. Pyxis Oncology's average media sentiment score of 0.00 equaled Contineum Therapeutics'average media sentiment score.

Company	Overall Sentiment
Pyxis Oncology	Neutral
Contineum Therapeutics	Neutral

Contineum Therapeutics' return on equity of -27.09% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-135.60%	-85.00%
Contineum Therapeutics	N/A	-27.09%	-25.64%

Contineum Therapeutics has higher revenue and earnings than Pyxis Oncology. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	10.28	-$79.62M	-$1.31	N/A
Contineum Therapeutics	$50M	10.12	-$59.98M	-$1.95	N/A

Pyxis Oncology has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market.

Pyxis Oncology currently has a consensus price target of $6.86, indicating a potential upside of 204.76%. Contineum Therapeutics has a consensus price target of $20.00, indicating a potential upside of 47.82%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, equities analysts clearly believe Pyxis Oncology is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Pyxis Oncology beats Contineum Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Pyxis Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PYXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PYXS vs. The Competition

Export

Metric	Pyxis Oncology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$149.52M	$3.07B	$6.90B	$12.28B
Dividend Yield	N/A	2.05%	2.67%	9.36%
P/E Ratio	-1.72	12.37	22.26	21.51
Price / Sales	10.28	340.68	517.96	91.07
Price / Cash	N/A	27.11	26.68	47.25
Price / Book	2.62	4.20	10.66	6.14
Net Income	-$79.62M	$65.94M	$3.60B	$331.74M
7 Day Performance	-7.79%	-3.04%	-1.51%	-1.72%
1 Month Performance	10.84%	-1.30%	1.11%	-1.44%
1 Year Performance	99.12%	16.06%	23.77%	16.97%

Pyxis Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PYXS Pyxis Oncology	2.5683 of 5 stars	$2.25 -4.7%	$6.86 +204.8%	+108.8%	$149.52M	$13.86M	N/A	60
FBRX Forte Biosciences	2.2123 of 5 stars	$43.36 -1.7%	$67.00 +54.5%	+380.0%	$599.33M	N/A	N/A	5
DNA Ginkgo Bioworks	1.2912 of 5 stars	$8.99 -0.7%	$8.50 -5.4%	-22.2%	$589.51M	$170.15M	N/A	640	News Coverage Analyst Forecast
IMMX Immix Biopharma	3.6382 of 5 stars	$10.78 +2.4%	$20.67 +91.8%	+245.1%	$587.30M	N/A	N/A	9	News Coverage Gap Down
ALT Altimmune	1.8544 of 5 stars	$2.95 -1.5%	$15.71 +433.6%	-29.7%	$570.77M	$40K	N/A	50

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PYXS) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pyxis Oncology (PYXS) Competitors

PYXS vs. FBRX, DNA, IMMX, ALT, and CTNM

How does Pyxis Oncology compare to Forte Biosciences?

Summary

How does Pyxis Oncology compare to Ginkgo Bioworks?

Summary

How does Pyxis Oncology compare to Immix Biopharma?

Summary

How does Pyxis Oncology compare to Altimmune?

Summary

How does Pyxis Oncology compare to Contineum Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYXS vs. The Competition

Pyxis Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pyxis Oncology (PYXS) Competitors

PYXS vs. FBRX, DNA, IMMX, ALT, and CTNM

How does Pyxis Oncology compare to Forte Biosciences?

Does the media favor PYXS or FBRX?

Which has better valuation and earnings, PYXS or FBRX?

Do institutionals and insiders hold more shares of PYXS or FBRX?

Which has more volatility & risk, PYXS or FBRX?

Do analysts recommend PYXS or FBRX?

Is PYXS or FBRX more profitable?

Summary

How does Pyxis Oncology compare to Ginkgo Bioworks?

Is PYXS or DNA more profitable?

Does the media refer more to PYXS or DNA?

Do analysts recommend PYXS or DNA?

Which has better earnings & valuation, PYXS or DNA?

Which has more risk and volatility, PYXS or DNA?

Do insiders & institutionals hold more shares of PYXS or DNA?

Summary

How does Pyxis Oncology compare to Immix Biopharma?

Which has more risk and volatility, PYXS or IMMX?

Which has higher earnings and valuation, PYXS or IMMX?

Is PYXS or IMMX more profitable?

Do analysts rate PYXS or IMMX?

Does the media favor PYXS or IMMX?

Do institutionals and insiders hold more shares of PYXS or IMMX?

Summary

How does Pyxis Oncology compare to Altimmune?

Which has more volatility & risk, PYXS or ALT?

Which has higher earnings & valuation, PYXS or ALT?

Do analysts rate PYXS or ALT?

Do institutionals and insiders have more ownership in PYXS or ALT?

Is PYXS or ALT more profitable?

Does the media prefer PYXS or ALT?

Summary

How does Pyxis Oncology compare to Contineum Therapeutics?

Do insiders and institutionals believe in PYXS or CTNM?

Does the media favor PYXS or CTNM?

Is PYXS or CTNM more profitable?

Which has higher earnings and valuation, PYXS or CTNM?

Which has more volatility & risk, PYXS or CTNM?

Do analysts recommend PYXS or CTNM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYXS vs. The Competition

Pyxis Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools